Premium
Biogen Inc (BIIB)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-01 | Mr. Adam KeeneyExec. VP & Head of Corporate Development | -455,00 | 85,11k | Derivative Exercise and Sale | 187,06 | 6,37k | - |
| 2026-05-01 | Mr. Adam KeeneyExec. VP & Head of Corporate Development | 484,00 | 0,00 | Derivative Exercise and Retained Stock | - | 6,37k | 8,23% |
| 2026-04-01 | Mr. Sean GodboutVP, CAO & Global Corporate Controller | -54,00 | 9,92k | Derivative Exercise and Sale | 183,78 | 1,34k | - |
| 2026-04-01 | Mr. Sean GodboutVP, CAO & Global Corporate Controller | 127,00 | 0,00 | Derivative Exercise and Retained Stock | - | 1,34k | 10,45% |
| 2026-02-12 | Ms. Nicole MurphyExec. VP and Head of Pharmaceutical Operations & Technology | 3,00 | 585,11 | Achat | 195,04 | 19,61k | 0,02% |
| 2026-02-06 | Mr. Christopher A. ViehbacherPresident, CEO & Director | 13,48k | 0,00 | Derivative Exercise and Retained Stock | - | 29,92k | 81,99% |
| 2026-02-06 | Mr. Christopher A. ViehbacherPresident, CEO & Director | -10,98k | 2,21M | Derivative Exercise and Sale | 201,18 | 29,92k | - |
| 2026-02-06 | Dr. Priya SinghalExec. VP & Head of Development | 1,77k | 0,00 | Derivative Exercise and Retained Stock | - | 8,04k | 28,26% |
| 2026-02-06 | Dr. Priya SinghalExec. VP & Head of Development | -5,13k | 1,03M | Derivative Exercise and Sale | 199,83 - 201,18 | 8,04k | - |
| 2026-02-06 | Ms. Nicole MurphyExec. VP and Head of Pharmaceutical Operations & Technology | 5,39k | 0,00 | Derivative Exercise and Retained Stock | - | 19,61k | 37,87% |
| 2026-02-06 | Ms. Nicole MurphyExec. VP and Head of Pharmaceutical Operations & Technology | -3,34k | 671,74k | Derivative Exercise and Sale | 201,18 | 19,61k | - |
| 2026-02-06 | Ms. Robin C. KramerExec. VP & CFO | 3,46k | 0,00 | Derivative Exercise and Retained Stock | - | 11,47k | 43,19% |
| 2026-02-06 | Ms. Robin C. KramerExec. VP & CFO | -1,54k | 310,42k | Derivative Exercise and Sale | 201,18 | 11,47k | - |
| 2026-02-06 | Mr. Adam KeeneyExec. VP & Head of Corporate Development | 3,50k | 0,00 | Derivative Exercise and Retained Stock | - | 5,88k | 146,69% |
| 2026-02-06 | Mr. Adam KeeneyExec. VP & Head of Corporate Development | -1,58k | 318,47k | Derivative Exercise and Sale | 201,18 | 5,88k | - |
| 2026-02-06 | Mr. Rachid IzzarExec. VP and Head of Global Product Strategy & Commercialization | 4,85k | 0,00 | Derivative Exercise and Retained Stock | - | 11,01k | 78,75% |
| 2026-02-06 | Mr. Rachid IzzarExec. VP and Head of Global Product Strategy & Commercialization | -2,04k | 410,00k | Derivative Exercise and Sale | 201,18 | 11,01k | - |
| 2026-02-06 | Dr. Jane GroganExec. VP & Head of Research | 2,27k | 0,00 | Derivative Exercise and Retained Stock | - | 4,06k | 126,58% |
| 2026-02-06 | Dr. Jane GroganExec. VP & Head of Research | -991,00 | 199,37k | Derivative Exercise and Sale | 201,18 | 4,06k | - |
| 2026-02-06 | Dr. Ginger GregoryExec. VP & Chief HR Officer | 4,59k | 0,00 | Derivative Exercise and Retained Stock | - | 22,36k | 25,86% |
| 2026-02-06 | Dr. Ginger GregoryExec. VP & Chief HR Officer | -2,59k | 520,86k | Derivative Exercise and Sale | 201,18 | 22,36k | - |
| 2026-02-06 | Mr. Sean GodboutVP, CAO & Global Corporate Controller | 720,00 | 0,00 | Derivative Exercise and Retained Stock | - | 1,22k | 145,45% |
| 2026-02-06 | Mr. Sean GodboutVP, CAO & Global Corporate Controller | -359,00 | 72,22k | Derivative Exercise and Sale | 201,18 | 1,22k | - |
| 2026-02-06 | Ms. Susan H. AlexanderInitié | 5,54k | 0,00 | Derivative Exercise and Retained Stock | - | 61,89k | 9,84% |
| 2026-02-06 | Ms. Susan H. AlexanderInitié | -3,50k | 704,93k | Derivative Exercise and Sale | 201,18 | 61,89k | - |
| 2026-01-30 | Dr. Priya SinghalExec. VP & Head of Development | 499,00 | 0,00 | Derivative Exercise and Retained Stock | - | 6,27k | 8,65% |
| 2026-01-30 | Dr. Priya SinghalExec. VP & Head of Development | -1,33k | 238,81k | Derivative Exercise and Sale | 179,30 - 179,89 | 6,27k | - |
| 2025-12-01 | Mr. Christopher A. ViehbacherPresident, CEO & Director | 3,64k | 0,00 | Derivative Exercise and Retained Stock | - | 16,44k | 28,39% |
| 2025-12-01 | Mr. Christopher A. ViehbacherPresident, CEO & Director | -3,40k | 605,16k | Derivative Exercise and Sale | 177,78 | 16,44k | - |
| 2025-10-31 | Dr. Jane GroganExec. VP & Head of Research | 358,00 | 0,00 | Derivative Exercise and Retained Stock | - | 1,79k | 24,98% |
| 2025-10-31 | Dr. Jane GroganExec. VP & Head of Research | -337,00 | 51,99k | Derivative Exercise and Sale | 154,27 | 1,79k | - |
| 2025-10-02 | Mr. Sean GodboutVP, CAO & Global Corporate Controller | 18,00 | 0,00 | Derivative Exercise and Retained Stock | - | 495,00 | 3,77% |
| 2025-10-02 | Mr. Sean GodboutVP, CAO & Global Corporate Controller | -8,00 | 1,24k | Derivative Exercise and Sale | 155,25 | 495,00 | - |
| 2025-08-29 | Dr. Priya SinghalExec. VP & Head of Development | 345,00 | 0,00 | Derivative Exercise and Retained Stock | - | 5,77k | 6,36% |
| 2025-08-29 | Dr. Priya SinghalExec. VP & Head of Development | -1,32k | 175,75k | Derivative Exercise and Sale | 132,22 - 133,55 | 5,77k | - |
| 2025-07-08 | Mr. Rachid IzzarExec. VP and Head of Global Product Strategy & Commercialization | -2,22k | 300,11k | Vente | 135,00 | 6,33k | -25,99% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
